Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease.
The present study was carried out to elucidate the beneficial effect of pioglitazone in cognitive impairment induced by bilateral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in substantia nigra pars compacta (SNc) in rats, a model of Parkinson's disease. MPTP-lesioned rats showed poor cognitive performance in both passive avoidance task and cued version of the Morris water maze test. This deficit in learning and memory was found to be associated with oxidative stress. Chronic administration of pioglitazone (10 and 30 mg/kg, p.o., starting 5 days prior to MPTP administration and then for next 30 days) in MPTP-lesioned rats improved cognitive performance in passive avoidance task and cued version of the Morris water maze test. Furthermore, pioglitazone treatment also reduced oxidative stress (as evident by reduced malondialdehyde and increased glutathione levels). These results demonstrate the beneficial effects of pioglitazone on cognitive impairment in MPTP induced Parkinson's disease in rats.
Kumar
Pramod
P
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Sector-67, S.A.S. Nagar, Punjab 160062, India.
Kaundal
Ravinder K
RK
More
Sandeep
S
Sharma
Shyam S
SS
D000284:Administration, Oral; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects / Q000502:physiology; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D004193:Discrimination Learning / Q000187:drug effects / Q000502:physiology; D004195:Disease Models, Animal; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D005978:Glutathione / Q000378:metabolism; D015227:Lipid Peroxidation / Q000187:drug effects; D020267:MPTP Poisoning / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D008297:Male; D008315:Malondialdehyde / Q000032:analysis; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D008568:Memory / Q000187:drug effects / Q000502:physiology; D000077205:Pioglitazone; D051381:Rats; D017208:Rats, Wistar; D013037:Spatial Behavior / Q000187:drug effects / Q000502:physiology; D013053:Spectrophotometry; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*
D045162:Thiazolidinediones; D008315:Malondialdehyde; D005978:Glutathione; D000077205:Pioglitazone